Trade Mark Journal No.2026/012 20 March 2026
WO0000001905172 (5,42)
Office of origin: United States of America
Date of International Registration:3 February 2026
Date of designation in the UK:
3 February 2026
International priority date claimed: 4 August 2025
(Tonga)
- Class 5
- Pharmaceuticals; pharmaceutical preparations; pharmaceuticals for the treatment of mental health conditions; pharmaceutical preparations for the treatment of mental health conditions; pharmaceutical preparations, namely, psychotropic, psychoactive, and psychedelic medicinal preparations for the treatment of mental health conditions; pharmaceutical preparations for the treatment of psychiatric diseases and disorders, namely, anxiety, depression, post-traumatic stress disorder, and mood disorders; pharmaceutical preparations for the treatment of substance-use and addictive disorders.
- Class 42
- Drug discovery services; pharmaceutical drug development services; pharmaceutical research and development; pharmaceutical research services; providing medical and scientific research information in the fields of pharmaceuticals; research and development in the pharmaceutical and biotechnology fields; pharmaceutical research and development in the fields of psychiatry, neurology, and addiction medicine; medical and scientific research, namely, conducting clinical trials for others in the field of psychedelic-based therapeutics.
Definium Therapeutics US, Inc.
Representative: John Paul Oleksiuk Cooley LLP, 1299 Pennsylvania Ave. NW STE 700, Washington DC 20004, UNITED STATES OF AMERICA